AlphaMaven AlphaMaven

Kotak Mahindra MF buys Rs 612 crore worth Emcure shares from Bain Capital, promoter sells 2.8% stake in...

Reported by Moneycontrol
Jun 9, 2026· 2 min read
Save Post LinkedIn Email
Key Takeaways
  • • Kotak Mahindra Mutual Fund acquired Rs 612 crore worth of Emcure Pharmaceuticals shares from Bain Capital, representing a significant institutional entry into the pharma company's cap table ahead of its IPO.
  • • Bain Capital divested nearly 1% of its stake in Emcure through the transaction at an average price of Rs 1,608.20 per share, generating approximately Rs 289 crore from the block deal, while retaining a 13.07% stake post-divestment.
  • • Emcure's IPO (scheduled for July 3–5, 2026) includes a total public offering size of Rs 1,952 crore, comprising Rs 800 crore in fresh issuance and Rs 1,152 crore in offer for sale from promoter Satish Mehta and BC Investments IV Ltd (Bain Capital affiliate).
  • • Anchor investors, including HDFC Mutual Fund, ICICI Prudential MF, SBI MF, and international allocators such as Abu Dhabi Investment Authority and Goldman Sachs Asset Management, committed Rs 583 crore at Rs 1,008 per share, signaling strong institutional confidence.
  • • Post-IPO market capitalization is projected to exceed Rs 19,000 crore, with promoter Satish Mehta retaining a 41.85% stake and Bain Capital maintaining a meaningful presence as a significant minority shareholder.
Summary
Kotak Mahindra Mutual Fund has completed a Rs 612 crore acquisition of Emcure Pharmaceuticals shares from Bain Capital ahead of the company's planned IPO launch on July 3, 2026. This transaction reflects continued institutional accumulation in the Pune-based pharmaceutical manufacturer, which has attracted significant investor interest prior to its public market debut.

Bain Capital, which has backed Emcure since before its IPO filing, executed the stake reduction through open market transactions and a block deal mechanism. The divestment generated Rs 289 crore for Bain at an average share price of Rs 1,608.20, representing a controlled partial exit while maintaining a material 13.07% stake post-transaction. This strategic reduction aligns with typical private equity liquidation timelines ahead of public market flotation, allowing Bain to realize returns while retaining exposure to further upside.

The IPO structure comprises Rs 800 crore in fresh equity issuance and an Rs 1,152 crore offer for sale from existing stakeholders, aggregating to Rs 1,952 crore at the upper end of the price band (Rs 960–Rs 1,008 per share). Anchor book allocation reached Rs 583 crore across 48 institutional funds, including domestic heavyweight HDFC Mutual Fund, ICICI Prudential MF, and SBI MF, alongside international allocators including AbuDhabi Investment Authority, Goldman Sachs Asset Management, and Nomura. This anchor commitment at Rs 1,008 per share underscores strong institutional conviction in Emcure's growth trajectory and valuations.

Promoter Satish Mehta will retain a 41.85% stake post-IPO, ensuring founder alignment with public shareholders. Brokerage consensus values the company at over Rs 19,000 crore post-issuance. Proceeds from fresh issuance will be deployed toward debt reduction and general corporate purposes, strengthening Emcure's balance sheet ahead of scaled operations.

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

1 outlet

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

Moneycontrol Kotak Mahindra MF buys Rs 612 crore worth Emcure shares from Bain Capital, promoter sells 2.8% stake in...